Corrigendum to "Complete inactivation of venezuelan equine encephalitis virus by 1,5-iodonaphthylazide" [Biochem. Biophys. Res. Commun. 358 (2007) 392-398] (DOI:10.1016/j.bbrc.2007.04.115);Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide

Biochemical and Biophysical Research Communications

Volumn 358, Issue 2, 2007, Pages 392-398

  Sharma, Anuj ^a,b   Raviv, Yossef ^c,d   Puri, Anu ^c   Viard, Mathias ^c,d   Blumenthal, Robert ^c   Maheshwari, Radha K ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

1,5 Iodonaphthyl azide; Inactivation; Photoactive; Venezuelan equine encephalitis Virus

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IRRADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS TITRATION;

MUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 34248584605     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.08.117     Document Type: Erratum

References (39)

1. Smith D.R., Aguilar P.V., Coffey L.L., Gromowski G.D., Wang E., and Weaver S.C. Venezuelan equine encephalitis virus transmission and effect on pathogenesis. Emerg. Infect. Dis. 12 (2006) 1190-1196
2. Weaver S.C. Host range, amplification and arboviral disease emergence. Arch. Virol. Suppl. (2005) 33-44
3. Ferro C., Boshell J., Moncayo A.C., Gonzalez M., Ahumada M.L., Kang W., and Weaver S.C. Natural enzootic vectors of Venezuelan equine encephalitis virus, Magdalena valley, Colombia. Emerg. Infect. Dis. 9 (2003) 49-54
4. Bowen G.S., and Calisher C.H. Virological and serological studies of Venezuelan equine encephalomyelitis in humans. J. Clin. Microbiol. 4 (1976) 22-27
5. Grieder F.B., Davis N.L., Aronson J.F., Charles P.C., Sellon D.C., Suzuki K., and Johnston R.E. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206 (1995) 994-1006
6. Charles P.C., Walters E., Margolis F., and Johnston R.E. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 208 (1995) 662-671
7. J.F. Smith, K. Davis, M.K. Hart, G.V. Ludwig, D.J. McClain, M.D. Parker, Viral encephalitides, vol. 1, Office of the Surgeon General, Washington DC, 1997.
8. Weaver S.C., Ferro C., Barrera R., Boshell J., and Navarro J.C. Venezuelan equine encephalitis. Annu. Rev. Entomol. 49 (2004) 141-174
9. Steele K.E., Davis K.J., Stephan K., Kell W., Vogel P., and Hart M.K. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice. Vet. Pathol. 35 (1998) 386-397
10. Hawley R.J., and Eitzen Jr. E.M. Biological weapons-a primer for microbiologists. Annu. Rev. Microbiol. 55 (2001) 235-253
11. Pittman P.R., Makuch R.S., Mangiafico J.A., Cannon T.L., Gibbs P.H., and Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14 (1996) 337-343
12. Engler R.J., Mangiafico J.A., Jahrling P., Ksiazek T.G., Pedrotti-Krueger M., and Peters C.J. Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine. J. Med. Virol. 38 (1992) 305-310
13. Alevizatos A.C., McKinney R.W., and Feigin R.D. Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. Am. J. Trop. Med. Hyg. 16 (1967) 762-768
14. Henderson B.E., Chappell W.A., Johnston Jr. J.G., and Sudia W.D. Experimental infection of horses with three strains of Venezuelan equine encephalomyelitis virus. I. Clinical and virological studies. Am. J. Epidemiol. 93 (1971) 194-205
15. Ludwig G.V., Turell M.J., Vogel P., Kondig J.P., Kell W.K., Smith J.F., and Pratt W.D. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am. J. Trop. Med. Hyg. 64 (2001) 49-55
16. Raviv Y., Bercovici T., Gitler C., and Salomon Y. Selective photoinduced uncoupling of the response of adenylate cyclase to gonadotropins by 5-iodonaphthyl 1-azide. Biochemistry 23 (1984) 503-508
17. Raviv Y., Salomon Y., Gitler C., and Bercovici T. Selective labeling of proteins in biological systems by photosensitization of 5-iodonaphthalene-1-azide. Proc. Natl. Acad. Sci. USA 84 (1987) 6103-6107
18. Kahane I., and Gitler C. Red cell membrane glycophorin labeling from within the lipid bilayer. Science 201 (1978) 351-352
19. Holowka D., Gitler C., Bercovici T., and Metzger H. Reaction of 5-iodonaphthyl-1-nitrene with the IgE receptor on normal and tumour mast cells. Nature 289 (1981) 806-808
20. Jorgensen P.L., Karlish S.J., and Gitler C. Evidence for the organization of the transmembrane segments of (Na,K)-ATPase based on labeling lipid-embedded and surface domains of the alpha-subunit. J. Biol. Chem. 257 (1982) 7435-7442
21. Pak C.C., Krumbiegel M., Blumenthal R., and Raviv Y. Detection of influenza hemagglutinin interaction with biological membranes by photosensitized activation of [125I]iodonaphthylazide. J. Biol. Chem. 269 (1994) 14614-14619
22. Bercovici T., and Gitler C. 5-[125I]Iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Biochemistry 17 (1978) 1484-1489
23. Raviv Y., Viard M., Bess Jr. J.W., Chertova E., and Blumenthal R. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J. Virol. 79 (2005) 12394-12400
24. Maheshwari R.K., Sidhu G.S., Bhartiya D., and Freedman R.M. Primary amines enhance the antiviral activity of interferon against a member virus: role of intracellular pH. J. Gen. Virol. 72 (1991) 2143-2152
25. Berge T.O., Banks I.S., and Tigertt W.D. Attenuation of Venezuelan equine encephalomyelitis vaccine by in vitro cultivation in guinea-pig heart cells. Am. J. Hyg. 73 (1961) 209-218
26. Walton T.E., Alvarez Jr. O., Buckwalter R.M., and Johnson K.M. Experimental infection of horses with an attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83). Infect. Immun. 5 (1972) 750-756
27. Reed D.S., Lind C.M., Lackemeyer M.G., Sullivan L.J., Pratt W.D., and Parker M.D. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine 23 (2005) 3139-3147
28. Rao V., Hinz M.E., Roberts B.A., and Fine D. Toxicity assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526. Vaccine 24 (2006) 1710-1715
29. Pratt W.D., Davis N.L., Johnston R.E., and Smith J.F. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21 (2003) 3854-3862
30. Hart M.K., Caswell-Stephan K., Bakken R., Tammariello R., Pratt W., Davis N., Johnston R.E., Smith J., and Steele K. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 18 (2000) 3067-3075
31. Paessler S., Ni H., Petrakova O., Fayzulin R.Z., Yun N., Anishchenko M., Weaver S.C., and Frolov I. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses. J. Virol. 80 (2006) 2784-2796
32. Hodgson L.A., Ludwig G.V., and Smith J.F. Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 17 (1999) 1151-1160
33. Phillpotts R.J., O'Brien L., Appleton R.E., Carr S., and Bennett A. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 23 (2005) 1615-1623
34. Bennett A.M., Lescott T., and Phillpotts R.J. Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus. Viral Immunol. 11 (1998) 109-117
35. Phillpotts R.J., Jones L.D., and Howard S.C. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 20 (2002) 1497-1504
36. Phillpotts R.J. Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res. 120 (2006) 107-112
37. Greenway T.E., Eldridge J.H., Ludwig G., Staas J.K., Smith J.F., Gilley R.M., and Michalek S.M. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine. Vaccine 16 (1998) 1314-1323
38. Negrette B., Bonilla E., Valero N., Giraldoth D., Medina-Leendertz S., and Anez F. In mice the efficiency of immunization with Venezuelan Equine Encephalomyelitis virus TC-83 is transiently increased by dehydroepiandrosterone. Invest. Clin. 42 (2001) 235-240
39. Negrette B., Bonilla E., Valero N., Pons H., Garcia Tamayo J., Chacin-Bonilla L., Medina-Leendertz S., and Anez F. Melatonin treatment enhances the efficiency of mice immunization with Venezuelan equine encephalomyelitis virus TC-83. Neurochem. Res. 26 (2001) 767-770